Endometrial Cancer Trial, Recruiting NCT04504006 Sponsor: Dr. Paul Buderath Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04504006
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with uterine cancer (endometrial carcinoma), confirmed by a tissue test, at stages I to III
  • Your cancer is either the common type (endometrioid) or a less common type (non-endometrioid) of uterine cancer
  • You are well enough to have surgery, with a general health score of 70 or above on a standard medical scale (confirm with trial site)
  • You are 18 years of age or older
  • You have completed treatment either through a specific surgical approach used in this trial (called Cohort A), or through standard treatment following established European guidelines (called Cohort B)
  • You are willing and able to give your informed consent to take part

Who may not be able to join:

  • Your uterine cancer is a pure sarcoma (a specific type that starts in muscle or connective tissue)
  • Your cancer has spread to distant parts of the body (distant metastases)
  • You have certain connective tissue diseases, such as scleroderma, lupus, or mixed connective tissue disease
  • You have or have had another separate cancer
  • You have previously had radiotherapy (radiation treatment) to the pelvis
  • You are pregnant
  • You received radiotherapy after surgery, unless it was given specifically because cancer cells were left behind after surgery or five or more lymph nodes were affected — in those cases, joining the Cohort A group may still be possible (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rainer Kimmig, Prof., University Hospital, Essen

Phone: +492017232442

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Dr. Paul Buderath
Registry
ClinicalTrials.gov
Start date
10 October 2017
Est. completion
1 January 2025

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Progression Free Survival; Intra- and postoperative complications, incidence of lymph oedema

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov